Merry Christmas and a Happy New Year 2022
The year 2021 is drawing to a close and I can’t help but take stock after this second pandemic year, as it was a moving year.
Continue readingThe year 2021 is drawing to a close and I can’t help but take stock after this second pandemic year, as it was a moving year.
Continue readingThe data and facts on pediatric MS show that consistent immunotherapy is indicated even in childhood to control the further course of the disease. This is contrasted by the fact that most MS therapies approved
Continue readingI would like to preface this by saying that I am not a neuropediatrician and also not an expert on childhood MS. Therefore, I have not written a post on this topic so far, although
Continue readingI would have very much wished not to have to write about this complex of topics anymore – but the current situation makes the topic of vaccination against COVID19 very topical again – and the
Continue readingOne of the most exciting topics of large international congresses is the outlook for new therapies that may be able to bring added value in the future. As an immunological treatment strategy, we will probably
Continue readingThe pandemic and the discussions about vaccinating MS patients against COVID19 have shown the need for a common European approach regarding recommendations for vaccinating MS sufferers. Therefore, after the last ECTRIMS Congress in 2020, representatives
Continue readingHow long should immunotherapy for MS be continued? When can therapy be stopped? These are questions that not only concern MS patients but also many neurologists. Of course, one can take the position that long-lasting
Continue readingThis year, the ECTRIMS Congress was again held virtually due to the pandemic. While this was a pity, as large international congresses thrive on the personal exchange between doctors and scientists, there was still plenty
Continue readingThe vaccination campaign against COVID19 has been underway for quite some time now. It is somewhat disappointing that fewer people could be convinced of the usefulness of a vaccination than one had hoped – but
Continue readingThere is news about Natalizumab (Tysabri®), which was expected, but it is still good that clarity now exists: In August 2021, the first results of the NOVA study were communicated, which compared the effectiveness of
Continue readingUnsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.